 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Send article |  RSS-Feed
U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN16 May 2007 -
Oncolytics Biotech Inc. announced that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).
The trial is expected to enroll up to 47 patients with metastatic melanoma. This cancer indication was selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill melanoma cells.
Additional information
National Cancer Institute (NCI)
United States of America
News
|
Oncolytics Biotech Inc
Calgary, AB, Canada
Company
News
|
U. S. Food and Drug Administration (FDA)
Rockville, MD, United States of America
News
|
|
|
|
|
|
Top
